Interpretations of “Diagnosis and Treatment Protocol for Novel Coronavirus Pneumonia (Trial Version 7)”

Since the outbreak of coronavirus disease 2019 (COVID-19), the National Health Commission of the People's Republic of China has issued a series of timely updated guidelines. [5–8] Type II alveolar epithelial cells show extensive hyperplasia, with some necrosis and desquamation. [...]latest research has confirmed the postmortem persistence of 2019-nCoV in the lung tissue of the patients who experienced diffuse alveolar damage followed by rapidly evolving pulmonary fibrosis and respiratory failure. [...]several complications, such as acute cardiac injury, acute kidney injury, abnormal coagulation function, shock, and even multi-organ dysfunction, tend to develop in critically ill patients. The previous clinical experience suggests that some patients with mild and moderate disease would inevitably evolve into critically ill states or may even die during hospitalization. [...]the prognostic factors for patients at risk of developing more severe disease are of paramount importance in strengthening surveillance and enabling timely initiation of appropriate treatment.